Centessa Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CNTA)

Key Points

• Unusual options activity: Traders bought 2,994 call options (about a 472% jump vs. normal), consistent with bullish positioning as the stock surged to $39.99 on dramatically above‑average volume.
• Eli Lilly acquisition and valuation: Eli Lilly agreed to acquire Centessa for an initial ~$6.3 billion (potentially up to ~$7.8 billion with milestones), citing Centessa’s OX2R agonist sleep‑wake program; analysts’ consensus is a "Moderate Buy" with a ~$40 target.
• Risks and insider activity: Halper Sadeh LLC is probing whether shareholders are getting a fair price (which could prompt legal action or a higher bid), while insiders have recently sold sizable positions—introducing execution and perception risk.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock investors acquired 2,994 call options on the stock. This is an increase of approximately 472% compared to the typical daily volume of 523 call options.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on CNTA shares. TD Cowen restated a "buy" rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Wolfe Research started coverage on Centessa Pharmaceuticals in a report on Tuesday, February 24th. They set an "outperform" rating and a $40.00 price objective on the stock. Piper Sandler reissued an "overweight" rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Finally, Chardan Capital restated a "buy" rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.00.

More Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa in a multi‑billion dollar deal that values the company at an initial ~$6.3 billion with potential to rise (reports cite up to $7.8B including milestones). The acquisition validates Centessa’s sleep‑wake OX2R agonist program and is the primary driver of the share rise. Read More. Read More.
• Positive Sentiment: Centessa’s pipeline and strategic fit: Lilly emphasized Centessa’s OX2R agonists as potentially best‑in‑class candidates to treat excessive daytime sleepiness and narcolepsy, which supports premium pricing for the deal and long‑term value for shareholders. Read More.
• Positive Sentiment: Unusual options activity: Large call buying was reported (nearly a 5x jump vs. typical call volume), consistent with bullish positioning tied to the takeover news and expectations of an offer-related premium. (Entry: unusual options trading reported 3/31)
• Neutral Sentiment: Analyst stance: Needham reaffirmed a "hold" on the stock — a sign analysts are waiting for deal closing and final terms rather than changing near‑term views immediately. Read More.
• Neutral Sentiment: Trading mechanics: Volume surged well above average and the stock is trading far above its 50‑ and 200‑day moving averages, reflecting deal news and momentum rather than company operational updates. (Background trading data)
• Negative Sentiment: Potential shareholder challenge / fairness probe: Halper Sadeh LLC is investigating whether Centessa’s shareholders are receiving a fair price, which could lead to legal scrutiny or demands for a higher bid and introduce execution risk or delay. Read More.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Iqbal J. Hussain sold 38,951 shares of the firm's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider owned 57,645 shares in the company, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the sale, the insider directly owned 65,925 shares of the company's stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 349,073 shares of company stock worth $9,429,412 over the last ninety days. 7.09% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in CNTA. Avoro Capital Advisors LLC boosted its stake in Centessa Pharmaceuticals by 34.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company's stock valued at $364,034,000 after purchasing an additional 3,747,475 shares during the period. Adage Capital Partners GP L.L.C. increased its position in Centessa Pharmaceuticals by 12.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company's stock worth $282,156,000 after buying an additional 1,246,741 shares during the period. Farallon Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 24.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company's stock worth $134,480,000 after buying an additional 1,045,750 shares during the last quarter. Siren L.L.C. boosted its position in shares of Centessa Pharmaceuticals by 24.8% in the fourth quarter. Siren L.L.C. now owns 4,027,517 shares of the company's stock valued at $100,728,000 after acquiring an additional 800,000 shares during the period. Finally, Commodore Capital LP grew its stake in shares of Centessa Pharmaceuticals by 39.3% in the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company's stock worth $43,340,000 after acquiring an additional 930,711 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Performance

CNTA traded up $12.41 during trading on Tuesday, hitting $39.99. The stock had a trading volume of 23,121,596 shares, compared to its average volume of 1,771,957. The firm has a market cap of $5.84 billion, a PE ratio of -21.85 and a beta of 1.54. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $40.26. The company has a 50 day simple moving average of $25.96 and a 200-day simple moving average of $25.12.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.